Literature DB >> 6650978

Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii.

C H Ahn, J R Lowell, S S Ahn, S I Ahn, G A Hurst.   

Abstract

Forty patients with pulmonary disease caused by Mycobacterium kansasii were treated initially with rifampin, isoniazid, and ethambutol daily for 12 months, and with streptomycin twice weekly for the first 3 months. Postchemotherapy follow-up examinations have ranged from 6 to 68 months, with an average of 31 months. One of the 40 patients (2.5%) relapsed 6 months after completion of chemotherapy. In vitro susceptibility of the mycobacteria to the drugs used, extent of disease, and/or the coexistence of other diseases did not seem to influence the outcome. This 12-month chemotherapy regimen is considered to be sufficient for the initial treatment of pulmonary disease caused by M. kansasii.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6650978     DOI: 10.1164/arrd.1983.128.6.1048

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  12 in total

1.  Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

Review 2.  Treatment of pulmonary disease caused by opportunist mycobacteria.

Authors:  J Banks
Journal:  Thorax       Date:  1989-06       Impact factor: 9.139

3.  Mycobacterium kansasii and Pneumocystis carinii pneumonia in a patient with the acquired immunodeficiency syndrome.

Authors:  U Vurma-Rapp; F Colla; M Flepp
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

4.  Infection with Mycobacterium kansasii.

Authors:  P D Davies
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

5.  Treatment of Non-Tuberculous Mycobacterial Lung Disease.

Authors:  Julie V Philley; Mary Ann DeGroote; Jennifer R Honda; Michael M Chan; Shannon Kasperbauer; Nicholas D Walter; Edward D Chan
Journal:  Curr Treat Options Infect Dis       Date:  2016-10-11

6.  Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

7.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

8.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

Review 9.  Nontuberculous mycobacterial pulmonary diseases in immunocompetent patients.

Authors:  Won-Jung Koh; O Jung Kwon; Kyung Soo Lee
Journal:  Korean J Radiol       Date:  2002 Jul-Sep       Impact factor: 3.500

10.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.